Tirzepatide Brand Comparison
Mounjaro vs Zepbound: Same Molecule, Two Brand Names
Mounjaro and Zepbound are not two different drugs. Both contain tirzepatide (LY3298176), the same dual GIP/GLP-1 receptor agonist manufactured by Eli Lilly. The brands exist because tirzepatide received separate FDA approvals for two different indications.
Key Takeaways
- Same molecule: Both Mounjaro and Zepbound contain tirzepatide (LY3298176), a dual GIP/GLP-1 agonist made by Eli Lilly. Pharmacokinetics are identical.
- Different indications: Mounjaro is FDA-approved for type 2 diabetes (2022). Zepbound is FDA-approved for chronic weight management and obstructive sleep apnea (2023/2024).
- Same dosing: Both start at 2.5 mg once weekly and titrate up to 15 mg max. The schedule is identical.
- Different formulations: Mounjaro is available as KwikPen only. Zepbound adds single-dose vials as a lower-cost option.
- Cost varies by coverage: List prices are similar (~$1,079/month Mounjaro vs ~$1,086/month Zepbound), but insurance coverage differs significantly based on indication.
- Clinical outcomes are identical: No trial has shown one brand outperforms the other. They cannot, because they are the same molecule.
20.9%
Max weight loss (SURMOUNT-1, 15 mg, 72 wks)
~5 days
Identical half-life for both brands
3
Total FDA approvals across both brands
What Are Mounjaro and Zepbound? The One-Sentence Answer
Mounjaro vs Zepbound is not a question about two different drugs. Both are brand names for tirzepatide (LY3298176), a dual GIP and GLP-1 receptor agonist developed and manufactured by Eli Lilly. They received separate FDA approvals because the clinical development program pursued two distinct indications: type 2 diabetes management and chronic weight management. The molecule is the same in both boxes.
The molecule behind both brands
Tirzepatide activates two hormone receptors simultaneously: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). GLP-1 activation reduces appetite, slows gastric emptying, and improves insulin sensitivity. GIP activation contributes additional metabolic effects and works synergistically with GLP-1 to produce greater weight loss than either pathway alone.
This dual-agonist mechanism is why tirzepatide outperforms semaglutide (a GLP-1-only agonist) in head-to-head trials. In SURMOUNT-1, participants on 15 mg tirzepatide lost an average of 20.9% of body weight at 72 weeks, and 57% of participants lost at least 20% of their starting weight. These are outcomes for the molecule. They apply equally to Mounjaro and Zepbound because the molecule is identical in both.
FDA approval timeline
| Brand | Indication | Approval |
|---|---|---|
| Mounjaro | Type 2 diabetes management | May 2022 |
| Zepbound | Chronic weight management (BMI ≥30, or ≥27 with comorbidity) | November 2023 |
| Zepbound | Moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity | December 2024 |
Sources: FDA Mounjaro Prescribing Information (2022); FDA Zepbound Prescribing Information (2023); FDA OSA Approval Press Release (December 2024).
Mounjaro vs Zepbound: Side-by-Side Comparison
| Feature | Mounjaro | Zepbound |
|---|---|---|
| Molecule | Tirzepatide (LY3298176) | Tirzepatide (LY3298176) |
| Mechanism | Dual GIP/GLP-1 agonist | Dual GIP/GLP-1 agonist |
| Developer | Eli Lilly | Eli Lilly |
| FDA-approved indication | Type 2 diabetes | Chronic weight management; obstructive sleep apnea |
| Year approved | 2022 | 2023 (weight); 2024 (OSA) |
| Dose range | 2.5 mg to 15 mg weekly | 2.5 mg to 15 mg weekly |
| Half-life | Approximately 5 days | Approximately 5 days |
| Delivery device | KwikPen (prefilled single-use autoinjector) only | KwikPen + single-dose vials |
| List price (approx.) | ~$1,079/month | ~$1,086/month |
| Insurance landscape | More commonly covered (T2D indication) | Less commonly covered (obesity indication often excluded) |
| Best candidate | Patients with type 2 diabetes | Patients with obesity or overweight with comorbidity, including OSA |
Dosing: Is the Titration Schedule the Same?
Yes. Mounjaro and Zepbound follow an identical titration protocol. Both start at 2.5 mg once weekly for 4 weeks, then increase by 2.5 mg every 4 weeks as tolerated, up to a maximum of 15 mg once weekly. The schedule is not determined by brand; it is determined by the FDA-approved prescribing information for tirzepatide and by individual patient tolerability.
Tirzepatide has a half-life of approximately 5 days, meaning each weekly injection keeps drug levels relatively stable between doses. Steady-state concentrations are reached after about 4 weeks of once-weekly dosing, according to the label. For full titration tables, visit the complete tirzepatide dosing guide or the tirzepatide dosage chart. This article summarizes the shared schedule rather than repeating all that detail.
Shared titration summary: 2.5 mg (wks 1-4) → 5 mg (wks 5-8) → 7.5 mg (wks 9-12) → 10 mg (wks 13-16) → 12.5 mg (wks 17-20) → 15 mg maintenance. This schedule applies to both Mounjaro and Zepbound.
Delivery device differences
This is one of the few real practical differences. Mounjaro is available only as a KwikPen, a prefilled single-use autoinjector. Zepbound offers the same KwikPen format but also provides single-dose vials, introduced by Lilly as a lower-cost pathway sold through LillyDirect.
The vial option matters for cost-conscious patients, particularly those without insurance coverage for Zepbound. Vials require drawing up a dose using a separate syringe rather than the autoinjector mechanism.
If you are using compounded tirzepatide, neither brand distinction applies. Compounded tirzepatide uses the same active molecule from 503A/503B pharmacies. See the compounded tirzepatide guide for details on that pathway.
Visualize Your Tirzepatide Schedule
Whether you take Mounjaro or Zepbound, the pharmacokinetics are identical. Use GLP3Planner's free calculator to model your drug levels and plan your titration.
Weight Loss Results: Does One Brand Outperform the Other?
No. There is no clinical evidence that Zepbound produces different weight loss outcomes than Mounjaro, or vice versa. The clinical trials that established tirzepatide's efficacy studied the molecule. The SURMOUNT program tested tirzepatide, not a brand name.
SURMOUNT-1 enrolled 2,539 adults with obesity or overweight without type 2 diabetes. At the 15 mg dose over 72 weeks, participants lost an average of 20.9% of body weight; 57% achieved at least a 20% reduction. These numbers are tirzepatide numbers. They apply to whichever brand name is on the prescription.
Why trial data can appear different for Mounjaro vs Zepbound
Some sources cite lower weight loss percentages in connection with Mounjaro than Zepbound. This reflects a population difference, not a drug difference. The SURMOUNT trials enrolled people with obesity (Zepbound's indication). The SURPASS trials enrolled people with type 2 diabetes (Mounjaro's indication). Type 2 diabetes patients often have different baseline metabolic profiles, hormonal responses, and medications that collectively moderate observed weight-loss percentages.
To be specific: presenting SURMOUNT results as "Zepbound data" and SURPASS results as "Mounjaro data" would be misleading, because both trials studied tirzepatide. Both sets of outcomes belong to the molecule. The population enrolled in each trial differs, which produces different observed weight loss ranges, but neither number tells you whether one brand is superior.
Common misconception: Some competitor content states Zepbound users lose approximately 22% while Mounjaro users lose approximately 15%. This misrepresents different trial populations as brand differences. Neither claim reflects a pharmacological distinction between the brands. Do not make treatment decisions based on that framing.
Side Effects: Same Drug, Same Side Effects
Because Mounjaro and Zepbound contain identical tirzepatide, they produce the same side effect profile. There is no brand-specific side effect. Patients switching from one to the other do not experience a different set of reactions.
The most common side effects reported in SURMOUNT-1 are nausea, diarrhea, constipation, and vomiting. These are mostly mild to moderate in severity and are dose-dependent, meaning they tend to appear or worsen during dose increases and improve once the body adjusts to a new dose level.
Most common side effects (applies to both brands)
- Nausea (especially during titration)
- Diarrhea
- Constipation
- Vomiting
For side effect frequencies by dose and timing, visit tirzepatide side effects: what to expect and how to manage.
Cost and Insurance: Where Mounjaro and Zepbound Actually Differ
This is where the real-world distinction matters. The pharmacology is identical, but the financial experience of getting either drug is often very different depending on your insurance.
Approximate list prices (wholesale acquisition cost): Mounjaro approximately $1,079 per month; Zepbound approximately $1,086 per month. The difference is small in absolute terms. What matters far more is whether your insurance covers the drug at all.
What insurance covers Zepbound in 2026?
Coverage varies by plan type. Mounjaro is FDA-approved for type 2 diabetes, and most employer health plans and pharmacy benefit managers cover diabetes medications. Zepbound is approved for weight management, and obesity drug coverage is frequently excluded from employer plan formularies.
ACA marketplace plans differ by state and insurer. Some state Medicaid programs cover Zepbound; most do not as of 2026. Medicare Part D traditionally excludes weight-loss drugs by statute, though legislative activity around this continues. Always verify current coverage directly with your insurer before assuming coverage in either direction.
Eli Lilly offers savings programs for both brands for eligible commercially insured patients. The specific values of these programs change and cannot be reliably cited here. Visit Lilly's official websites for current program terms.
Compounded tirzepatide as an alternative
If neither brand is covered, compounded tirzepatide from 503A or 503B pharmacies costs significantly less. Because compounded versions use the active tirzepatide molecule, they share the same pharmacokinetic profile as both brands.
Regulatory status for compounded tirzepatide has evolved alongside FDA shortage determinations. For current sourcing, cost comparison, and quality considerations, see the compounded tirzepatide guide and the tirzepatide cost guide.
Which Should You Ask Your Doctor For?
Because the molecule is identical, the choice between Mounjaro and Zepbound comes down to three things: your diagnosis, your insurance, and which formulation you prefer.
1. You have type 2 diabetes
Ask about Mounjaro. It carries the T2D FDA indication. Insurer adjudication of diabetes medications is far more favorable than obesity drug coverage in most plan types.
2. You have obesity or overweight with comorbidities (no T2D)
Ask about Zepbound. It holds the weight management and OSA indications. If you have moderate-to-severe sleep apnea, Zepbound's OSA indication may strengthen your coverage argument with your insurer.
3. Your insurance covers neither brand
Discuss compounded tirzepatide or alternative GLP-1 options with your prescriber. For a comparison of tirzepatide against semaglutide-based options (Wegovy, Ozempic), see the tirzepatide vs semaglutide comparison.
Note: GLP3Planner does not provide medical advice. These frameworks are educational. Your prescriber makes the clinical determination based on your full medical history.
Video: Who Can Take Which GLP-1 Medication?
Ohio State Wexner Medical Center breaks down which GLP-1 medication is prescribed for which indication, including the Mounjaro vs Zepbound distinction. Over 2.7 million views.
Tracking Your Tirzepatide Dose
The math works the same whether your box says Mounjaro or Zepbound. GLP3Planner's free tirzepatide calculator models drug levels using exponential decay based on tirzepatide's approximately 5-day half-life. You can see how levels build across your titration schedule, when you hit steady state, and share your plan via a token link.
GLP3Planner supports tirzepatide, Mounjaro, and Zepbound calculator modes. All use the same underlying pharmacokinetic model because the molecule is the same.
Frequently Asked Questions
Are Mounjaro and Zepbound the exact same drug?
Yes. Both Mounjaro and Zepbound contain tirzepatide (LY3298176), an identical dual GIP and GLP-1 receptor agonist manufactured by Eli Lilly. They differ only in their FDA-approved indications: Mounjaro for type 2 diabetes (approved 2022), Zepbound for chronic weight management and obstructive sleep apnea (approved 2023 and 2024). The molecule, dosing schedule, pharmacokinetics, and side effect profile are the same.
Does Zepbound work better than Mounjaro for weight loss?
No. Because they contain identical tirzepatide, neither brand can outperform the other. Clinical trial data showing up to 20.9% body weight loss at 72 weeks (SURMOUNT-1) and 57% of participants losing at least 20% reflects the molecule's effect, not a brand-specific outcome. Apparent differences in published trial results come from different study populations (obesity trials vs. type 2 diabetes trials), not from any difference between the brands.
Why does my insurance cover Mounjaro but not Zepbound?
Mounjaro is FDA-approved for type 2 diabetes, and most insurers cover diabetes medications. Zepbound is approved for weight management, and many employer plans and Medicare Part D explicitly exclude weight-loss drugs from coverage. Insurance companies adjudicate based on the FDA indication listed on the claim, not the molecular content of the drug. The same tirzepatide molecule gets covered for one indication and denied for another because of how coverage categories are structured.
What is the difference between Mounjaro and Zepbound formulations?
Mounjaro is available only as a KwikPen (prefilled single-use autoinjector). Zepbound is available as a KwikPen and also as single-dose vials, which Lilly introduced as a lower-cost alternative through LillyDirect. Both formats cover all doses from 2.5 mg through 15 mg. The vial option requires drawing up the dose separately, while the KwikPen delivers a fixed dose with a push of a button.
Can I switch from Zepbound to Mounjaro or vice versa?
Yes, and no dose adjustment is needed because both contain the same tirzepatide at the same doses. Switching is typically driven by insurance changes (for example, a formulary update that covers one brand and not the other), not by clinical preference. Confirm the switch with your prescriber to maintain continuity of your prescription and coverage, and to ensure supply timing aligns.
What does Zepbound treat that Mounjaro does not?
Zepbound holds two FDA-approved indications that Mounjaro does not: chronic weight management in adults with BMI of 30 or higher (or 27 with at least one weight-related condition), and moderate-to-severe obstructive sleep apnea in adults with obesity, approved December 2024. Mounjaro's sole approved indication is type 2 diabetes management. Pharmacologically the drugs are identical; the indications reflect separate regulatory approvals from separate clinical programs.
Is tirzepatide the same as Mounjaro and Zepbound?
Yes. Tirzepatide is the nonproprietary (generic) name for the active molecule. Mounjaro and Zepbound are brand names for tirzepatide, the same way ibuprofen is the generic name and Advil or Motrin are brand names for that compound. Eli Lilly manufactures all three. The terms are interchangeable at the molecular level; they differ only in labeling, packaging, and FDA-approved indication.
What are the side effects of Mounjaro vs Zepbound?
Side effects are identical because the molecule is identical. The most common are nausea, diarrhea, constipation, and vomiting, mostly mild to moderate and dose-dependent. Side effects typically peak during dose escalation and diminish as the body adjusts. No brand-specific side effect profile has been observed or reported in clinical data from either the SURMOUNT or SURPASS trial programs.
Which is cheaper, Mounjaro or Zepbound?
List prices are similar at approximately $1,079 per month for Mounjaro and approximately $1,086 per month for Zepbound. Out-of-pocket cost depends heavily on insurance coverage. Mounjaro is more often covered for T2D patients. Zepbound vials may offer a lower-cost pathway for uninsured patients through LillyDirect compared to KwikPens of either brand. For a full cost breakdown including compounded options, see the tirzepatide cost guide.
What is the titration schedule for Mounjaro and Zepbound?
Both use an identical titration: start at 2.5 mg once weekly for 4 weeks, then increase by 2.5 mg increments every 4 weeks as tolerated, up to a maximum of 15 mg once weekly. The escalation schedule is driven by tolerability, not brand. Tirzepatide's half-life is approximately 5 days; steady-state levels are reached about 4 weeks after each dose change. For full titration tables, see the complete tirzepatide dosing guide.
References
- U.S. Food and Drug Administration. Mounjaro (tirzepatide) injection, for subcutaneous use. Prescribing Information. Silver Spring, MD: FDA; 2022. accessdata.fda.gov
- U.S. Food and Drug Administration. Zepbound (tirzepatide) injection, for subcutaneous use. Prescribing Information. Silver Spring, MD: FDA; 2023. accessdata.fda.gov
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038
- U.S. Food and Drug Administration. FDA Approves New Treatment for Adults with Moderate-to-Severe Obstructive Sleep Apnea. FDA News Release. June 21, 2024. fda.gov
- Aronne LJ, et al. Tirzepatide versus semaglutide once weekly in patients with obesity (SURMOUNT-5). N Engl J Med. 2025. doi:10.1056/NEJMoa2410516
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Mounjaro and Zepbound are prescription medications. Consult a qualified healthcare provider before starting, stopping, or changing any medication.
Related Articles
Tirzepatide Hub
Complete guide to Mounjaro and Zepbound: mechanism, trials, dosing, calculators.
Complete Tirzepatide Dosing Guide
Full titration tables, SURMOUNT data, and clinical protocol details.
Tirzepatide Side Effects Guide
Common and serious side effects of Mounjaro and Zepbound with management tips.
Compounded Tirzepatide Guide
Cost-effective alternative when brand coverage fails. Sourcing, quality, and dosing.
Tirzepatide Cost in 2026
Brand vs compounded pricing, savings cards, and insurance strategies.
Tirzepatide vs Semaglutide
Head-to-head comparison of the dual-agonist vs GLP-1 only class.